摘要
目的:探讨厚朴酚对非小细胞肺癌(NSCLC)获得性紫杉醇耐药细胞的影响。方法:人NSCLC Calu3细胞在培养中单独使用紫杉醇间歇性处理或与厚朴酚联用处理3个月后,分离细胞并在体外检测其药物敏感性,使用MTT法检测药物诱导的生长抑制,通过测量细胞中P糖蛋白(Pgp)荧光底物钙黄绿素的积累来定量Pgp外排活性。结果:连续使用紫杉醇处理会导致紫杉醇耐药性的发展,并对多药耐药性Pgp底物产生交叉耐药性,而厚朴酚/紫杉醇的组合阻止耐药性的发展,并且细胞仍具有化学敏感性。当用联合方案治疗耐药细胞时,可以克服紫杉醇耐药性。结论:厚朴酚/紫杉醇联合用药可抑制耐药性的发展并逆转紫杉醇耐药性,使紫杉醇耐药细胞重新对紫杉醇敏感。
Objective: To determine the effect of magnolol on the development of acquired paclitaxel resistance in non-small cell lung cancer(NSCLC).Methods: During the culture of human NSCLC Calu3 cells,paclitaxel was used alone in a inter-mittent treatment or combined with magnolol for 3 months,and the cells were isolated and the drug sensitivity was characterized in vitro.MTT was used to measure the drug-induced growth inhibition,and Pgp efflux activity was quantified by measuring the accumulation of Pgp fluorescent substrate calcein in cells.Results: Intermittent treatment with paclitaxel led to the development of paclitaxel resistance and cross-resistance to the multidrug-resistant P-glycoprotein substrate,while the combination of magnolol/paclitaxel prevented the development of drug resistance and the cells remained chemically sensitive.When the combined therapy was used to treat the resistant cells,paclitaxel resistance could be overcome.Conclusion: The combination of magnolol/paclitaxel can inhibit the development of drug resistance and overcome paclitaxel resistance to make paclitaxel-resistant cells resusceptible to paclitaxel.
作者
陈恩就
周方联
陈胜
Chen Enjiu;Zhou Fanglian;Chen Sheng(Department of Respiratory,Affiliated Pingyang Hospital of Wenzhou Medical University,Zhejiang Pingyang 325400,China)
出处
《中国药师》
CAS
2021年第3期437-441,共5页
China Pharmacist
基金
科技部国家重点研发计划中医药现代化研究重点专项(编号:2019YFC1711200)
陕西省自然科学基础研究计划(编号:2019JQ-874)
陕西省教育厅专项科研计划(编号:19JK0232)。
关键词
紫杉醇
厚朴酚
非小细胞肺癌
化疗敏感性
Paclitaxel
Magnolol
Non-small cell lung cancer
Chemotherapy sensitivity
